305 related articles for article (PubMed ID: 33477333)
1. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma.
Ong JR; Bamodu OA; Khang NV; Lin YK; Yeh CT; Lee WH; Cherng YG
Cells; 2021 Jan; 10(1):. PubMed ID: 33477333
[TBL] [Abstract][Full Text] [Related]
2. Increased Small Ubiquitin-like Modifier-Activating Enzyme SAE1 Promotes Hepatocellular Carcinoma by Enhancing mTOR SUMOylation.
Chen Y; Peng W; Tao Q; Li S; Wu Z; Zhou Y; Xu Q; Shu Y; Xu Y; Shao M; Chen M; Shi Y
Lab Invest; 2023 Jan; 103(1):100011. PubMed ID: 36748193
[TBL] [Abstract][Full Text] [Related]
3. Unveiling the Mystery of SUMO-activating enzyme subunit 1: A Groundbreaking Biomarker in the Early Detection and Advancement of Hepatocellular Carcinoma.
Wang H; Yang T; Wu J; Chen D; Wang W
Transplant Proc; 2023 May; 55(4):945-951. PubMed ID: 37236867
[TBL] [Abstract][Full Text] [Related]
4. SAE1 promotes human glioma progression through activating AKT SUMOylation-mediated signaling pathways.
Yang Y; Liang Z; Xia Z; Wang X; Ma Y; Sheng Z; Gu Q; Shen G; Zhou L; Zhu H; Xu N; Liang S
Cell Commun Signal; 2019 Jul; 17(1):82. PubMed ID: 31345225
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive and Integrative Analysis Reveals the Diagnostic, Clinicopathological and Prognostic Significance of Polo-Like Kinase 1 in Hepatocellular Carcinoma.
Lin P; Wen DY; Dang YW; He Y; Yang H; Chen G
Cell Physiol Biochem; 2018; 47(3):925-947. PubMed ID: 29843122
[TBL] [Abstract][Full Text] [Related]
6. Sulfiredoxin-1 is a promising novel prognostic biomarker for hepatocellular carcinoma.
Rao QW; Zhang SL; Guo MZ; Yuan FF; Sun JL; Qi F; Wang LS; Yang BW; Xia JL
Cancer Med; 2020 Nov; 9(22):8318-8332. PubMed ID: 32955798
[TBL] [Abstract][Full Text] [Related]
7. Bioinformatics-based analysis of SUMOylation-related genes in hepatocellular carcinoma reveals a role of upregulated SAE1 in promoting cell proliferation.
Liu Y; Wang X; Zeng X; Wu Y; Liu X; Tan J; Li X
Open Med (Wars); 2022; 17(1):1183-1202. PubMed ID: 35859792
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase Regulatory Subunit 2 Indicated Poor Prognosis and Facilitated Aggressive Phenotype of Hepatocellular Carcinoma.
Zhang J; Song Q; Liu J; Lu L; Xu Y; Zheng W
Dis Markers; 2019; 2019():8964015. PubMed ID: 31781310
[TBL] [Abstract][Full Text] [Related]
9. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
10. Increased SUMO-activating enzyme SAE1/UBA2 promotes glycolysis and pathogenic behavior of rheumatoid fibroblast-like synoviocytes.
Wang C; Xiao Y; Lao M; Wang J; Xu S; Li R; Xu X; Kuang Y; Shi M; Zou Y; Wang Q; Liang L; Zheng SG; Xu H
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32938830
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic value of chaperonin containing T-complex 1 subunit 3 in hepatocellular carcinoma: A Study based on microarray and RNA-sequencing with 4272 cases.
Hou JY; Wu HY; He RQ; Lin P; Dang YW; Chen G
Pathol Res Pract; 2019 Jan; 215(1):177-194. PubMed ID: 30473171
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Spondin-2 protein expression correlates with poor prognosis in hepatocellular carcinoma.
Feng Y; Hu Y; Mao Q; Guo Y; Liu Y; Xue W; Cheng S
J Int Med Res; 2019 Feb; 47(2):569-579. PubMed ID: 30318967
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs involved with hepatocellular carcinoma (Review).
Mao B; Wang G
Oncol Rep; 2015 Dec; 34(6):2811-20. PubMed ID: 26398882
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
Zhao X; Liu Y; Yu S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
[TBL] [Abstract][Full Text] [Related]
15. SUMO pathway components as possible cancer biomarkers.
Mattoscio D; Chiocca S
Future Oncol; 2015; 11(11):1599-610. PubMed ID: 26043214
[TBL] [Abstract][Full Text] [Related]
16. Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1) Acts as Diagnostic Biomarker and Adverse Prognostic Factor of Hepatocellular Carcinoma (HCC): Evidence from Bioinformatic Analysis.
Wang W; Zhu G; Lai S; Guo Y; Yin X; Chen D; Wen L
Med Sci Monit; 2020 Feb; 26():e919896. PubMed ID: 32090983
[TBL] [Abstract][Full Text] [Related]
17. DNA Primase Subunit 1 Expression in Hepatocellular Carcinoma and Its Clinical Implication.
Zhang Y; Li L; Liu R; Zeng C
Biomed Res Int; 2020; 2020():9689312. PubMed ID: 32908930
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implication of NQO1 overexpression in hepatocellular carcinoma.
Lin L; Sun J; Tan Y; Li Z; Kong F; Shen Y; Liu C; Chen L
Hum Pathol; 2017 Nov; 69():31-37. PubMed ID: 28964792
[TBL] [Abstract][Full Text] [Related]
19. The Expression and Prognostic Value of SUMO1-Activating Enzyme Subunit 1 and Its Potential Mechanism in Triple-Negative Breast Cancer.
Wang Q; Zhong W; Deng L; Lin Q; Lin Y; Liu H; Xu L; Lu L; Chen Y; Huang J; Jiang M; Xiao H; Zhang J; Li H; Lin Y; Song C; Lin Y
Front Cell Dev Biol; 2021; 9():729211. PubMed ID: 34621746
[No Abstract] [Full Text] [Related]
20. ROS-mediated up-regulation of SAE1 by Helicobacter pylori promotes human gastric tumor genesis and progression.
Shi L; Shangguan J; Lu Y; Rong J; Yang Q; Yang Y; Xie C; Shu X
J Transl Med; 2024 Feb; 22(1):148. PubMed ID: 38351014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
